For athletes subject to anti-doping regulations, semaglutide is not currently listed as a prohibited substance by the World Anti-Doping Agency (WADA)
To maximize benefits and limit harms, stakeholders must pair pharmaceutical advances with equitable access policies, rigorous longterm safety monitoring and integrated care strategies that treat obesity as the chronic disease it is.
Evernorth's study found that more than 50% of those who take GLP-1s stop doing so within 12 months, limiting the data available on the medications for longer periods
Patients should monitor for recurrence of side effects when resuming tirzepatide, especially gastrointestinal symptoms
It mainly promotes healing by improving blood flow, repairing tissues, and adjusting certain genes
Reports indicate that regulatory submission is expected to follow completion of these trials